Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proline plus empagliflozin tablets in abdominal obesity with type 2 diabetes
ChiCTR2500111560Phase 4Not yet recruiting
- Sponsor
- Shougang Shuigang Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin in type 2 diabetes mellitus (T2DM) and Abdominal adiposity (ABCD), sponsored by Shougang Shuigang Hospital. Primary endpoint: Triglycerides. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Abdominal adiposity (ABCD)
Beyond the preview
Go deeper on ChiCTR2500111560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111560.